Accelerating precision medicine in pancreatic cancer through definition of novel
Italian Ministry of Education, University and Research, Italy, NY, United States
Organisation/Company Università degli Studi di Verona Research Field Medical sciences Researcher Profile Recognised Researcher (R2) Leading Researcher (R4) First Stage Researcher (R1) Established Researcher (R3) Application Deadline 15 Apr 2026 - 13:00 (UTC) Country Italy Type of Contract To be defined Job Status Not Applicable Is the job funded through the EU Research Framework Programme? Not funded by a EU programme Is the Job related to staff position within a Research Infrastructure? No
Offer Description Predicting response to therapies is key to improving clinical outcomes in oncology. For this reason, clinical genomics allows for the identification of genetic variants with potential clinical relevance; however, even when these variants are classified as pathogenic, they do not always correspond to actual biological dependencies and may therefore be limited in guiding therapeutic choices or prognostic assessment. The project focuses on alterations in genes involved in DNA repair mechanisms, for which targeted therapies are available. Using patient-derived xenografts and organoids, extensively characterized at the molecular level, the response to drug treatments will be modeled in order to identify molecular signatures associated with durable responses and potential mechanisms of resistance.
For admission to the selection process referred to in Art. 1, potential candidates must fulfil the following requirements:
PhD in Molecular Medicine.
Possession of a scientific-disciplinary curriculum suitable for carrying out the research activity envisaged in this announcement.
Knowledge of the following foreign language: English.
Other requirements: documented research and/or development experience in the disciplinary sector: MEDS-09/A - Medical Oncology.
Eligibility of fellows: country of residence
AFRICA
EUROPE
OCEANIA
NORTH AMERICA
SOUTH AMERICA
ASIA
Eligibility of fellows: nationality
AFRICA
EUROPE
OCEANIA
NORTH AMERICA
SOUTH AMERICA
ASIA
Selection Process The competition will be carried out by an evaluation of titles and examination by means of an interview.
#J-18808-Ljbffr
Offer Description Predicting response to therapies is key to improving clinical outcomes in oncology. For this reason, clinical genomics allows for the identification of genetic variants with potential clinical relevance; however, even when these variants are classified as pathogenic, they do not always correspond to actual biological dependencies and may therefore be limited in guiding therapeutic choices or prognostic assessment. The project focuses on alterations in genes involved in DNA repair mechanisms, for which targeted therapies are available. Using patient-derived xenografts and organoids, extensively characterized at the molecular level, the response to drug treatments will be modeled in order to identify molecular signatures associated with durable responses and potential mechanisms of resistance.
For admission to the selection process referred to in Art. 1, potential candidates must fulfil the following requirements:
PhD in Molecular Medicine.
Possession of a scientific-disciplinary curriculum suitable for carrying out the research activity envisaged in this announcement.
Knowledge of the following foreign language: English.
Other requirements: documented research and/or development experience in the disciplinary sector: MEDS-09/A - Medical Oncology.
Eligibility of fellows: country of residence
AFRICA
EUROPE
OCEANIA
NORTH AMERICA
SOUTH AMERICA
ASIA
Eligibility of fellows: nationality
AFRICA
EUROPE
OCEANIA
NORTH AMERICA
SOUTH AMERICA
ASIA
Selection Process The competition will be carried out by an evaluation of titles and examination by means of an interview.
#J-18808-Ljbffr